Genetic landscape of rare autoinflammatory disease variants in Qatar and Middle Eastern populations through the integration of genomic datasets

Parul Sharma, Abhinav Jain, Vinod Scaria

Chr	Start	End	Ref	Alt	Func. refGene	Gene. refGene	GeneDetail.refGene	CLINSIG 20180930	CLNDBN	esp6500siall	ExAC ALL	1000g2015aug all	gnomAD exome ALL	Qatar AF	SIFT pred	Polyphen2 HVAR pred	CADD phred	ExonicFunc refGene	AAChange.refGene	PVS1	PS1	PS2	PS3	PS4	PM1	PM2	PM3	PM4	PM5	PM6	PP1	PP2	PP3	PP4	PP5	BA1	BS1	BS2	BS3	BS4	BP1	BP2	BP3	BP4	BP5	BP6	BP7	Final Annotation	avsnp147	ACMG classification	Other information
5	138856982	138856982	C	T	exonic	TMEM173	.	.	.	0.183454	0.2049	0.27496	0.2117	0.2149	D	D	28.4	nonsynonymous SNV	TMEM173:NM_198282:exon7:c.G878A:p.R293Q						PM1							PP2	PP3			BA1		BS2								PM1,PP2,PP3,BA1,BS2	rs7380824	Benign (I)	
5	138861078	138861078	C	T	exonic	TMEM173	.	.	.	0.104798	0.1834	0.203075	0.1946	0.1896	T	B	13.08	nonsynonymous SNV	TMEM173:NM_00130173 8:exon2:c.G212A:p.R71H,TMEM173:NM_198282:exon3:c.G212A:p.R71H						PM1							PP2				BA1		BS2				BP4				PM1,PP2,BA1,BS2,BP4	rs11554776	Benign (I)	
6	32811629	32811629	G	T	exonic	PSMB8	.	.	Benign/Likely_benign	Nakajo_syndrome	not_specified	0.127105	0.1453	0.151957	0.1438	0.06818	T	B	22.2	nonsynonymous SNV	PSMB8:NM_148919:exon1:c.C145A:p.Q49K												PP2				BA1		BS2				BP4		BP6		PP2,BA1,BS2,BP4,BP6	rs20715543	Benign (I)	
6	32825090	32825090	G	A	exonic	PSMB9	.	.	.	0.248045	0.2456	0.224441	0.2432	0.3129	T	B	14.26	nonsynonymous SNV	PSMB9:NM_002800:exon3:c.G179A:p.R60H						PM1							PP2				BA1		BS2				BP4				PM1,PP2,BA1,BS2,BP4	rs17587	Benign (I)	
6	138196066	138196066	T	G	exonic	TNFAIP3	.	.	not_provided	not_specified	0.141934	0.0613	0.139577	0.0534	0.05672	T	B	15.6	nonsynonymous SNV	TNFAIP3:NM_001270507:exon3:c.T380G:p.F127C,TNFAIP3:NM_001270508:exon3:c.T380G:p.F127C,TNFAIP3:NM_006290:exon3:c.T380G:p.F127C						PM1											BA1		BS2				BP4				PM1,BA1,BS2,BP4	rs2230926	Benign (I)	
11	117864083	117864083	A	G	exonic	IL10RA	.	.	Benign/Likely_benign	not_specified|Inflammatory_bowel_disease	0.119458	0.1316	0.0816693	0.1309	0.08657	T	B	11.09	nonsynonymous SNV	IL10RA:NM_001558:exon4:c.A475G:p.S159G												PP2				BA1		BS2				BP4	BP6			PP2,BA1,BS2,BP4,BP6	rs3135932	Benign (I)	
11	117869670	117869670	A	G	exonic	IL10RA	.	.	Benign	Inflammatory_bowel_disease|not_specified	0.728448	0.7381	0.811102	0.7416	0.2473	T	B	0.945	nonsynonymous SNV	IL10RA:NM_001558:exon7:c.A1051G:p.R351G												PP2				BA1		BS2				BP4	BP6			PP2,BA1,BS2,BP4,BP6	rs2229113	Benign (I)	
12	110013879	110013879	G	A	exonic	MVK	.	.	Benign/Likely_benign	not_specified|Mevalonic_aciduria|Hyperimmunoglobulin_D_with_periodic_fever|Methylmalonic_acidemia	0.116177	0.1017	0.0758786	0.101	0.1124	T	B	0.002	nonsynonymous SNV	MVK:NM_000431:exon3:c.G155A:p.S52N,MVK:NM_001114185:exon3:c.G155A:p.S52N,MVK:NM_001301182:exon3:c.G155A:p.S52N																			BA1		BS2				BP4	BP6		BA1,BS2,BP4,BP6	rs7957619	Benign (I)	
16	50744624	50744624	C	T	exonic	NOD2	.	.	Benign	Blau_syndrome|Crohn_disease|not_specified	0.197676	0.1844	0.102037	0.1889	0.1867	T	B	0.001	nonsynonymous SNV	NOD2:NM_001293557:exon3:c.C721T:p.P241S,NOD2:NM_022162:exon4:c.C802T:p.P268S							PP2						BA1		BS2				BP4	BP6		PP2,BA1,BS2,BP4,BP6	rs2066842	Benign (I)	
16	50757276	50757276	G	A	exonic	NOD2	.	.	Benign	Sarcoidosis_early-onset|Crohn_disease|Blau_syndrome	0.069021	0.0611	0.0333466	0.0626	0.09801	D	B	1.382	nonsynonymous SNV	NOD2:NM_001293557:exon8:c.G2782A:p.V928I,NOD2:NM_022162:exon9:c.G2863A:p.V955I							PP2						BA1	BS1	BS2				BP4	BP6		PP2,BA1,BS1,BS2,BP4,BP6	rs5743291	Benign (I)	
17	78171944	78171944	G	C	exonic	CARD14	.	.	Benign	not_specified	0.359142	0.3772	0.370208	0.372	0.4488	T	B	0.077	nonsynonymous SNV	CARD14:NM_052819:exon9:c.G930C:p.R310S,CARD14:NM_001257970:exon12:c.G1641C:p.R547S,CARD14:NM_024110:exon12:c.G1641C:p.R547S																	BA1		BS2				BP4	BP6		BA1,BS2,BP4,BP6	rs2066964	Benign (I)	
17	78178893	78178893	C	T	exonic	CARD14	.	.	Benign	not_specified	0.409322	0.4244	0.353035	0.4143	0.3941	D	B	25.8	nonsynonymous SNV	CARD14:NM_024110:exon18:c.C2458T:p.R820W													PP3				BA1		BS2						BP6		PP3,BA1,BS2,BP6	rs11652075	Benign (I)	
19	55450727	55450727	C	T	exonic	NLRP7	.	.	Benign/Likely_benign	Hydatidiform_mole|not_specified	0.141781	0.0586	0.125599	0.0523	0.09353	T	B	0.086	nonsynonymous SNV	NLRP7:NM_001127255:exon4:c.G1460A:p.G487E,NLRP7:NM_139176:exon4:c.G1460A:p.G487E,NLRP7:NM_206828:exon4:c.G1460A:p.G487E																	BA1		BS2				BP4	BP6		BA1,BS2,BP4,BP6	rs775881	Benign (I)	
19	55450746	55450746	C	T	exonic	NLRP7	.	.	Benign/Likely_benign	not_specified|Hydatidiform_mole	0.117484	0.0888	0.0908546	0.0869	0.1193	T	B	6.577	nonsynonymous SNV	NLRP7:NM_001127255:exon4:c.G1441A:p.A481T,NLRP7:NM_139176:exon4:c.G1441A:p.A481T,NLRP7:NM_206828:exon4:c.G1441A:p.A481T																	BA1		BS2				BP4	BP6		BA1,BS2,BP4,BP6	rs61747414	Benign (I)	
1	247582063	247582063	G	T	UTR5	NLRP3	NM_001079821:c.-34G>T;NM_001127461:c.-34G>T;NM_001127462:c.-34G>T;NM_183395:c.-34G>T;NM_001243133:c.-49G>T;NM_004895:c.-34G>T	Benign	.	0.041827	0.0367	0.0269569	0.0374	0.02841	.	.	.	.																				BS1	BS2							BP6		BS1,BS2,BP6	rs73136263	Benign (III)	
1	247582309	247582309	C	T	exonic	NLRP3	.	.	Benign/Likely_benign	not_specified|Chronic_infantile_neurological,_cutaneous_and_articular_syndrome|Familial_cold_autoinflammatory_syndrome|Familial_amyloid_nephropathy_with_urticaria_AND_deafness	0.000077	0.0016	0.0031948 9	0.0016	0.002931	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon1:c.C213T:p.A71A,NLRP3:NM_001243133:exon1:c.C207T:p.A69A,NLRP3:NM_004895:exon1:c.C213T:p.A71A,NLRP3:NM_183395:exon1:c.C213T:p.A71A,NLRP3:NM_001127461:exon2:c.C213T:p.A71A,NLRP3:NM_001079821:exon3:c.C213T:p.A71A						PM1																						BP6	BP7	PM1,BP6,BP7	rs200082602	Likely Benign (II)	
1	247586336	247586336	T	C	intronic	NLRP3	.	.	.	0	0	0.459665	0	0.4375	.	.	.	.																		BA1		BS2									BA1,BS2	rs3806265	Benign (I)	
1	247586920	247586920	T	G	intronic	NLRP3	.	.	.	0	0	0.919728	0	0.04545	.	.	.	.																		BA1		BS2									BA1,BS2	rs4925651	Benign (I)	
1	247587174	247587174	C	T	exonic	NLRP3	.	.	Benign/Likely_benign	Familial_cold_autoinflammatory_syndrome|Chronic_infantile_neurological,_cutaneous_and_articular_syndrome|Familial_amyloid_nephropathy_with_urticaria_AND_deafness	0.006459	0.0021	0.00798722	0.0016	0.001601	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon3:c.C429T:p.Y143Y,NLRP3:NM_001243133:exon3:c.C423T:p.Y141Y,NLRP3:NM_004895:exon3:c.C429T:p.Y143Y,NLRP3:NM_183395:exon3:c.C423T:p.Y143Y,NLRP3:NM_001127461:exon4:c.C429T:p.Y143Y,NLRP3:NM_001079821:exon5:c.C429T:p.Y143Y						PM1																						BP6	BP7	PM1,BP6,BP7	rs56710146	Likely Benign (II)	
1	247587408	247587408	C	T	exonic	NLRP3	.	.	Benign	not_specified|Familial_amyloid_nephropathy_with_urticaria_AND_deafness|Familial_cold_autoinflammatory_syndrome|Chronic_infantile_neurological,_cutaneous_and_articular_syndrome	0.115254	0.0817	0.116613	0.0797	0.09602	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon3:c.C663T:p.T221T,NLRP3:NM_001243133:exon3:c.C657T:p.T219T,NLRP3:NM_004895:exon3:c.C663T:p.T221T,NLRP3:NM_183395:exon3:c.C657T:p.T221T,NLRP3:NM_001127461:exon4:c.C663T:p.T221T,NLRP3:NM_001079821:exon5:c.C663T:p.T221T						PM1												BA1		BS2						BP6	BP7	PM1,BA1,BS2,BP6,BP7	rs7525979	Benign (I)	
1	247587477	247587477	G	A	exonic	NLRP3	.	.	Benign	not_specified|Chronic_infantile_neurological,_cutaneous_and_articular_syndrome|Familial_cold_autoinflammatory_syndrome|Familial_amyloid_nephropathy_with_urticaria_AND_deafness	0.405966	0.4996	0.38738	0.5034	0.4881	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon3:c.G732A:p.A244A,NLRP3:NM_001243133:exon3:c.G726A:p.A242A,NLRP3:NM_004895:exon3:c.G732A:p.A244A,NLRP3:NM_183395:exon3:c.G732A:p.A244A,NLRP3:NM_001127461:exon4:c.G732A:p.A244A,NLRP3:NM_001079821:exon5:c.G732A:p.A244A						PM1												BA1		BS2						BP6	BP7	PM1,BA1,BS2,BP6,BP7	rs3806268	Benign (I)	
1	247587681	247587681	C	T	exonic	NLRP3	.	.	Benign/Likely_benign	Familial_cold_urticaria|not_specified	0.001153	0.0012	0.000998403	0.0012	0.001172	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon3:c.C936T:p.D312D,NLRP3:NM_001243133:exon3:c.C930T:p.D310D,NLRP3:NM_004895:exon3:c.C936T:p.D312D,NLRP3:NM_183395:exon3:c.C936T:p.D312D,NLRP3:NM_001127461:exon4:c.C936T:p.D312D,NLRP3:NM_001079821:exon5:c.C936T:p.D312D						PM1																				BP6	BP7	PM1,BP6,BP7	rs143840033	Likely Benign (II)	
1	247587771	247587771	C	T	exonic	NLRP3	.	.	Benign/Likely_benign	not_specified|Familial_cold_autoinflammatory_syndrome	0.006151	0.0049	0.0017971 2	0.0052	0.001761	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon3:c.C1026T:p.P342P,NLRP3:NM_001243133:exon3:c.C1020T:p.P340P,NLRP3:NM_004895:exon3:c.C1026T:p.P342P,NLRP3:NM_183395:exon3:c.C1020T:p.P342P,NLRP3:NM_001127461:exon4:c.C1026T:p.P342P,NLRP3:NM_001079821:exon5:c.C1026T:p.P342P						PM1																				BP6	BP7	PM1,BP6,BP7	rs41311573	Likely Benign (II)	
1	247587783	247587783	G	A	exonic	NLRP3	.	.	Benign/Likely_benign	Familial_cold_urticaria|Familial_amyloid_nephropathy_with_urticaria_AND_deafness|Familial_cold_autoinflammatory_syndrome|Chronic_infantile_neurological,_cutaneous_and_articular_syndrome	0.000538	0.0015	0.00239617	0.0013	0.002137	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon3:c.G1038A:p.L346L,NLRP3:NM_001243133:exon3:c.G1032A:p.L344L,NLRP3:NM_004895:exon3:c.G1038A:p.L346L,NLRP3:NM_183395:exon3:c.G1038A:p.L346L,NLRP3:NM_001127461:exon4:c.G1038A:p.L346L,NLRP3:NM_001079821:exon5:c.G1038A:p.L346L						PM1																				BP6	BP7	PM1,BP6,BP7	rs180177471	Likely Benign (II)	
1	247587795	247587795	G	A	exonic	NLRP3	.	.	Benign/Likely_benign	not_specified|Chronic_infantile_neurological,_cutaneous_and_articular_syndrome|Familial_amyloid_nephropathy_with_urticaria_AND_deafness|Familial_cold_autoinflammatory_syndrome	0.000077	0.0061	0.0115815	0.0055	0.004706	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon3:c.G1050A:p.T350T,NLRP3:NM_001243133:exon3:c.G1044A:p.T348T,NLRP3:NM_004895:exon3:c.G1050A:p.T350T,NLRP3:NM_183395:exon3:c.G1050A:p.T350T,NLRP3:NM_001127461:exon4:c.G1050A:p.T350T,NLRP3:NM_001079821:exon5:c.G1050A:p.T350T						PM1													BS1								BP6	BP7	PM1,BS1,BP6,BP7	rs143140947	Likely Benign (I)	
1	247587982	247587982	C	T	exonic	NLRP3	.	.	Benign/Likely_benign	Familial_cold_urticaria|not_specified|Chronic_infantile_neurological,_cutaneous_and_articular_syndrome|Familial_cold_autoinflammatory_syndrome|Familial_amyloid_nephropathy_with_urticaria_AND_deafness	0.007304	0.0061	0.00379393	0.0062	0.001172	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon3:c.C1237T:p.L413L,NLRP3:NM_001243133:exon3:c.C1231T:p.L411L,NLRP3:NM_004895:exon3:c.C1237T:p.L413L,NLRP3:NM_183395:exon3:c.C1237T:p.L413L,NLRP3:NM_001127461:exon4:c.C1237T:p.L413L,NLRP3:NM_001079821:exon5:c.C1237T:p.L413L																										BP6	BP7	BP6,BP7	rs148478875	Likely Benign (II)	
1	247587996	247587996	C	T	exonic	NLRP3	.	.	Likely_benign	Chronic_infantile_neurological,_cutaneous_and_articular_syndrome|Familial_cold_autoinflammatory_syndrome|Familial_amyloid_nephropathy_with_urticaria_AND_deafness	0.000077	6.59E-05	0.000199681	8.13E-05	0.007812	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon3:c.C1251T:p.I417I,NLRP3:NM_001243133:exon3:c.C1245T:p.I415I,NLRP3:NM_004895:exon3:c.C1251T:p.I417I,NLRP3:NM_183395:exon3:c.C1251T:p.I417I,NLRP3:NM_001127461:exon4:c.C1251T:p.I417I,NLRP3:NM_001079821:exon5:c.C1251T:p.I417I																										BP6	BP7	BP6,BP7	rs139852370	Likely Benign (II)	
1	247588053	247588053	C	T	exonic	NLRP3	.	.	Benign	not_specified|Familial_cold_autoinflammatory_syndrome|Familial_amyloid_nephropathy_with_urticaria_AND_deafness|Chronic_infantile_neurological,_cutaneous_and_articular_syndrome	0.088959	0.101	0.0656949	0.1013	0.1507	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon3:c.C1308T:p.S436S,NLRP3:NM_001243133:exon3:c.C1302T:p.S434S,NLRP3:NM_004895:exon3:c.C1308T:p.S436S,NLRP3:NM_183395:exon3:c.C1308T:p.S436S,NLRP3:NM_001127461:exon4:c.C1308T:p.S436S,NLRP3:NM_001079821:exon5:c.C1308T:p.S436S																		BA1		BS2						BP6	BP7	BA1,BS2,BP6,BP7	rs34298354	Benign (I)	
1	247588351	247588351	C	T	exonic	NLRP3	.	.	Benign/Likely_benign	Familial_cold_urticaria|not_specified|Chronic_infantile_neurological,_cutaneous_and_articular_syndrome|Familial_amyloid_nephropathy_with_urticaria_AND_deafness|Familial_cold_autoinflammatory_syndrome	0.004768	0.0016	0.00678914	0.0013	0.001172	.	.	.	synonymous SNV	NLRP3:NM_001127462:exon3:c.C1606T:p.L536L,NLRP3:NM_001243133:exon3:c.C1600T:p.L534L,NLRP3:NM_004895:exon3:c.C1606T:p.L536L,NLRP3:NM_183395:exon3:c.C1606T:p.L536L,NLRP3:NM_001127461:exon4:c.C1606T:p.L536L,NLRP3:NM_001079821:exon5:c.C1606T:p.L536L																										BP6	BP7	BP6,BP7	rs116054301	Likely Benign (II)	
1	247588960	247588960	G	A	intronic	NLRP3	.	.	.	0	0	0.130591	0	0.1193	.	.	.	.																		BA1		BS2									BA1,BS2	rs3738447	Benign (I)	
1	247593142	247593142	A	G	intronic	NLRP3	.	.	.	0	0	0.123003	0	0.1193	.	.	.	.																		BA1		BS2									BA1,BS2	rs12060377	Benign (I)
1	247597180	247597180	T	C	intronic	NLRP3	.	.	.	0	0	0	0	0.1529	.	.	.	.								PM2												BS2									PM2,BS2	rs76911796	VUS
1	247597181	247597181	G	A	intronic	NLRP3	.	.	.	0	0	0	0	0.1529	.	.	.	.								PM2												BS2									PM2,BS2	rs148560736	VUS
1	247597208	247597208	T	G	intronic	NLRP3	.	.	.	0	0	0	0	0.4059	.	.	.	.								PM2												BS2									PM2,BS2	rs113666299	VUS
1	247597211	247597211	T	C	intronic	NLRP3	.	.	.	0	0	0	0	0.4	.	.	.	.								PM2												BS2									PM2,BS2	rs113695411	VUS
1	247597329	247597329	C	T	intronic	NLRP3	.	.	.	0	0	0.917732	0	0.04545	.	.	.	.																		BA1		BS2									BA1,BS2	rs12124866	Benign (I)
1	247597365	247597365	G	A	intronic	NLRP3	.	.	.	0.907427	0	0.788738	0	0.05682	.	.	.	.																		BA1		BS2									BA1,BS2	rs10925022	Benign (I)
1	247599139	247599139	G	C	intronic	NLRP3	.	.	.	0	0	0.042132 6	0	0.02841	.	.	.	.																			BS1	BS2									BS1,BS2	rs34777558	Benign (II)
1	247599232	247599232	G	A	intronic	NLRP3	.	.	.	0.496848	0.586	0.484026	0.5922	0.4716	.	.	.	.																		BA1		BS2									BA1,BS2	rs10754557	Benign (I)
1	247599513	247599513	T	C	intronic	NLRP3	.	.	.	0	0	0.0489217	0	0.02841	.	.	.	.																			BS1	BS2									BS1,BS2	rs76225363	Benign (II)
1	247600301	247600301	A	C	intronic	NLRP3	.	.	.	0	0	0.654353	0	0.4261	.	.	.	.																		BA1		BS2									BA1,BS2	rs1539019	Benign (I)
1	247608167	247608167	C	A	intronic	NLRP3	.	.	.	0.134861	0.1416	0.0972444	0.141	0.1648	.	.	.	.																		BA1		BS2									BA1,BS2	rs45624634	Benign (I)
2	113887207	113887207	T	C	exonic	IL1RN	.	.	Benign	Osteomyelitis,_sterile_multifocal,_with_periostitis_and_pustulosis|not_specified	0.206136	0.2491	0.191693	0.2574	0.1791	.	.	.	synonymous SNV	IL1RN:NM_173842:exon2:c.T171C:p.A57A,IL1RN:NM_005577:exon3:c.T117C:p.A39A,IL1RN:NM_173841:exon4:c.T189C:p.A63A,IL1RN:NM_173843:exon4:c.T89C:p.A23A,IL1RN:NM_001318914:exon5:c.T89C:p.A23A																		BA1		BS2						BP6	BP7	BA1,BS2,BP6,BP7	rs419598	Benign (I)

| | | |

6	138196060	138196060	C	T	exonic	TNFAIP3	.		Uncertain_significance	not_specified	0.005536	0.0017	0.0559042	0.0012	0.001594	D	B	15.11	SNV	nonsynonymous	TNFAIP3:NM_001270507:exon3:c.C374T:p.A125V,TNFAIP3:NM_001270508:exon3:c.C374T:p.A125V,TNFAIP3:NM_006290:exon3:c.C374T:p.c		PS3	PM1				PP3					PS3,PM1,PP3	rs5029941	Likely pathogenic (III)	PubMed: 20483768:PS3:Ledoux et al. (2010) noted that there are 2 nonsynonymous coding polymorphisms in the deubiquitinating (DUB) domain of TNFAIP3: phe127 to cys (F127C ; rs223092[illegible]), which is in high linkage disequilibrium with SLE risk variants in people of European descent, and ala125 to val (A125V; rs5029941). They performed a case-control study with 217 African-American SLE patients using these coding variants, along with 6 tagging SNPs in TNFAIP3, and identified a novel African-derived risk haplotype. Although F127C was associated with SLE risk in this African American population, the most significant SLE-associated risk variant was an African-derived tagging SNP, rs5029953 (p = 0.008; odds ratio = 1.6). The rare minor allele of A125V was associated with protection from SLE in African Americans (p = 0.05; odds ratio = 0.38) and with susceptibility to inflammatory bowel disease (IBD; 266800) (p = 0.027; odds ratio = 3.73). Enzymatic functional analysis showed that A125V was associated with diminished TNFAIP3 deubiquitinating activity, and computer modeling suggested that A125V altered the 3-dimensional structure of the DUB domain to a greater extent than F127C. PMID: 24489017
10	72358215	72358215	A	C	exonic	PRF1	.		.	.	0.000308	0.0004	0.000199681	0.0003	0.001639	T	B	0.005	SNV	nonsynonymous	PRF1:NM_001083116:exon3:c.T1262G:p.F421C,PRF1:NM_005041:exon3:c.T1262G:p.F421C			PM1								BS3		BP4			PM1,BS3,BP4	rs200534908	Likely Benign (II)	PMID: 20536654:BS3:Consistent with the above hypothesis, two mutations (the common polymorphism Ala91Val and Arg232His), complemented GME(AP)proximately 50% of wildtype PRF function in mouse CTLs, while the F421C mutation had essentially normal activity compared with wildtype PRF. However, none of the other cancer-associated mutants had any detectable activity in either RBL cells or primary CTLs
10	72358722	72358722	T	C	exonic	PRF1	.		Conflicting_interpretations_of_pathogenicity	Hemophagocytic_lymphohistiocytosis_familial,_2|Malignant_lymphoma,_non-Hodgkin|not_specified	0.008458	0.0052	0.0758786	0.005	0.001758	B	B	0.037	SNV	nonsynonymous	PRF1:NM_001083116:exon3:c.A755G:p.N252S,PRF1:NM_005041:exon3:c.A755G:p.N252S		PS4	PM1								BS3		BP4			PS4,PM1,BS3,BP4	rs28933375	VUS	PubMed: 10583959: In a patient with familial hemophagocytic lymphohistiocytosis (FHL2; 603553), Stepp et al. (1999) identified a 755A-G transition in the PRF1 gene, resulting in an asn252-ser (N252S) substitution. PP1 PubMed: 15459303, PubMed: 15659737 In a 27-year-old man with autoimmune lymphoproliferative syndrome (601859) who later developed a T-cell-rich, histiocyte-rich, diffuse large B-cell lymphoma (605027), Clementi et al. (2004) identified a heterozygous N252S mutation in the PRF1 gene and a heterozygous mutation in the FAS gene (134637). The FAS mutation was inherited from his healthy father and was also carried by his healthy brother, whereas the PRF1 mutation was inherited from his healthy mother. Clementi et al. (2004) noted that the N252S substitution occurs within the membrane attack complex of the perforin protein, a region involved in the pore-forming activity of the molecule. However, both the patient and his mother had normal levels of perforin and normal NK cell activity. The authors suggested that the combined effect of the 2 mutant genes contributed to the development of ALPS and lymphoma in this patient. Rieux-Laucat et al. (2005) cast doubt on the pathogenicity of the N252S mutation, and the primary authors provided a rebuttal (Clementi et al., 2005). PubMed: 15728124 Clementi et al. (2005) identified the N252S mutation in 1 of 660 (0.02%) control alleles, suggesting that it is a benign polymorphism. PMID: 16720838:PS4:N252S conferred an OR = 62.7 (P = .0016) for ALPS 18198357:PS4 :In both cohorts, allelic frequency of N252S was significantly higher in patients than in control subjects (combined cohorts: 1.5 vs. 0.4%; odds ratio 6.68 [95% CI 1.83–7.48]) PMC4184267 :PP4 One patient died of MAS: she carried the N252S PRF1 variant and showed reduced perforin expression. PMID 15755897:BS3 In contrast, expression and function of N252S-substituted perforin were normal Taken together, our data and epidemiologic studies9 indicate that the N252S substitution alone could not have been causative of disease but, rather, that an additional genetic defect(s) might have been responsible. We therefore concluded that N252S probably represents a neutral PRF1 polymorphism. note: THIS VARIANT IS RESPONSIBLE FOR CAUSING DISEASE IN COMPOUND HETEROZYGOUS STATE ONLY. OTHERWISE IT IS BENIGN POLYMORPHISM.
10	72358845	72358845	G	A	exonic	PRF1	.		Benign	.	0	0.0024	0.0029521	0.0022	0.002657	T	B	0.122	SNV	nonsynonymous	PRF1:NM_001083116:exon3:c.C832T:p.A211V,PRF1:NM_005041:exon3:c.C832T:p.A211V			PM1		PP1						BS3	BS4	BP4	BP6		PM1,PP1,BS3,BS4,BP4,BP6	rs368524364	Benign (III)	PMID: 21936944 BS3: Cr-release cytotoxicity assays were performed using p.Ala211Val perforin transfected RBL cells. The p. Ala211Val substitution showed normal WT perforin and lytic activity (Figure 2).BS4 and PP1: second cousin sister has mutation and affected by disease but mother and other members of family had mutation but they are free of disease
10	72360291	72360291	C	T	exonic	PRF1	.		.	.	0.000923	0.0005	0.000199681	0.0005	0.003529	D	B	18.12	SNV	nonsynonymous	PRF1:NM_001083116:exon2:c.G368A:p.R123H,PRF1:NM_005041:exon2:c.G368A:p.R123H							PP3									PP3	rs139336186	VUS	
10	72360387	72360387	G	A	exonic	PRF1	.		Conflicting_interpretations_of_pathogenicity	Hemophagocytic_lymphohistiocytosis_familial,_2|_susceptibility_to|not_provided|Familial_hemophagocytic_lymphohistiocytosis|not_specified	0.033754	0.0311	0.0131789	0.0294	0.005034	D	D	26	SNV	nonsynonymous	PRF1:NM_001083116:exon2:c.C272T:p.A91V,PRF1:NM_005041:exon2:c.C272T:p.A91V							PP3		BS1					PP3,BS1	rs35947132	VUS	
10	72360577	72360577	G	A	exonic	PRF1	.		.	.	0.00054	0.0013	0.000199681	0.0012	0.001779	D	P	21.1	SNV	nonsynonymous	PRF1:NM_001083116:exon2:c.C82T:p.R28C,PRF1:NM_005041:exon2:c.C82T:p.R28C		PS3					PP3									PS3,PP3	rs141660798	VUS	PMID:20019086:PS3:Repeated flow cytometry for perforin in cytotoxic lymphocytes and assessment of lytic NK cell function in Patient P54 showed intermediately decreased levels of perforin and lytic NK cell function (~20%).PMID: 23734337: Both PRF1A91V- and PRF1R28C-expressing lymphocytes exhibited severely impaired but measurable cytotoxic function.
10	72360648	72360648	C	T	exonic	PRF1	.		Conflicting_interpretations_of_pathogenicity	Aplastic_anemia	not_specified	Familial_hemophagocytic_lymphohistiocytosis	not_provided	0.026793	0.0116	0.0219649	0.0059	0.01705	D	B	19.06	SNV	nonsynonymous	PRF1:NM_001083116:exon2:c.G11A:p.R4H,PRF1:NM_005041:exon2:c.G11A:p.R4H							PP3		BS1	BS2				PP3,BS1,BS2	rs35418374	Benign (III)	
12	6442643	6442643	C	T	exonic	TNFRSF1A	.		Conflicting_interpretations_of_pathogenicity	TNF_receptor-associated_periodic_fever_syndrome_(TRAPS)	not_specified	not_provided	0.01384	0.0141	0.00599042	0.0132	0.009815	T	B	15.3	SNV	nonsynonymous	TNFRSF1A:NM_001346091:exon3:c.C38A:p.R13Q,TNFRSF1A:NM_001065:exon4:c.C362A:p.R121Q			PM1			PP2		BS1			BP4			PM1,PP2,BS1,BP4	rs4149584	Likely Benign (I)	
12	6443001	6443001	G	A	exonic	TNFRSF1A	.		Benign/Likely_benign	not_specified	Familial_Periodic_Fever	0.025373	0.0127	0.028155	0.0055	0.01361	D	D	22.2	SNV	nonsynonymous	TNFRSF1A:NM_001065:exon3:c.C224T:p.P75L			PM1			PP2	PP3	BS1	BS2			BP6	PM1,PP2,PP3,BS1,BS2,BP6	rs4149837	Benign (II)	
12	110017618	110017618	G	A	exonic	MVK	.		Conflicting_interpretations_of_pathogenicity	Hyperimmunoglobulin_D_with_periodic_fever	not_specified	0.002537	0.0007	0.00199681	0.0007	0.001063	T	B	0.002	SNV	nonsynonymous	MVK:NM_000431:exon4:c.G238A:p.V80I,MVK:NM_001114185:exon4:c.G238A:p.V80I,MVK:NM_001301182:exon4:c.G238A:p.V80I														BP4	rs76914224	VUS	
12	110019222	110019222	G	A	exonic	MVK	.		not_provided	Hyperimmunoglobulin_D_with_periodic_fever	0	2.47E-05	0	3.66E-05	0.001794	T	B	0.003	SNV	nonsynonymous	MVK:NM_000431:exon5:c.G394A:p.V132I,MVK:NM_001114185:exon5:c.G394A:p.V132I			PM1	PM2										BP4		PM1,PM2,BP4	rs104895336	VUS	PMID:15536479, PMID:25897835, PMID:19877056, PMID26935981
12	110034320	110034320	G	A	exonic	MVK	.		Pathogenic	Hyperimmunoglobulin_D_with_periodic_fever|Hyperimmunoglobulin_D_with_periodic_fever|Mevalonic_aciduria|not_provided	0.001692	0.0014	0	0.0016	0.003212	T	B	20.3	SNV	nonsynonymous	MVK:NM_001301182:exon10:c.G973A:p.V325I,MVK:NM_000431:exon11:c.G1129A:p.V377I,MVK:NM_001114185:exon11:c.G1129A:p.V377I		PS4		PM3		PP1			PP5				BP4		PS4,PM3,PP1,PP5,BP4	rs28934897	Likely pathogenic (III)	PS4 :PubMed: 10369261: In 4 patients with the hyper-IgD syndrome (HIDS; 260920), Houten et al. (1999) found a 1129G-A transition, resulting in a val377-ile-ile amino acid substitution. In 3 of the 4 patients, V377I was present in compound heterozygous state; in the fourth patient, V377I GME(AP)peared to be present in homozygous state. The V377I mutation was found in homozygous state in a family with HIDS studied by Drenth et al. (1999).PS4 PubMed: 11313768 In 16 unrelated patients with HIDS, Houten et al. (2001) detected the V377I mutation, including one sibship with homozygosity. PS4 PubMed: 11313769 Cuisset et al. (2001) detected the V377I mutation in 20 of 25 unrelated patients with HIDS, the majority of whom were of Dutch origin. PS4 PubMed: 15539479 D'Osualdo et al. (2005) identified the V377I mutation in 50% of mutant alleles in 15 unrelated Italian patients with HIDS. In 2 patients the V377I mutation was found in homozygous state. PMID: 24470648 : PP1, PM3 Mutation analysis of the MVK gene revealed that the girl was compound heterozygote for 2 mutations, c.803T>C (p.Ile268Thr) and c.1129G>A (p.Val377Ile), known to be associated with the HIDS phenotype. Genotyping of both parents revealed that both parents carried a heterozygous mutation of the MVK gene: mother, c.803T>C (p.Ile268Thr); father, c.1129G>A (p.Val377Ile).(As it is taken from mother and father then it is in trans). PMID: 23979089 PP1, PM3 MVK enzyme activity in lymphocytes was below 1% and genomic sequencing of the MVK gene revealed 2 compound heterozygous mutations: p.[Val377Ile]+[Tyr116His]. The patient's mother carried the heterozygous p.Tyr116His mutation, whereas the father had heterozygous p.Val377Ile mutation.
15	55520906	55520906	G	A	exonic	RAB27A	.		Likely_pathogenic	not_provided	0	8.30E-06	0	1.63E-05	0.005845	D	D	34	SNV	nonsynonymous	RAB27A:NM_004580:exon4:c.C244T:p.R82C,RAB27A:NM_183234:exon5:c.C244T:p.R82C,RAB27A:NM_183235:exon5:c.C244T:p.R82C,RAB27A:NM_183236:exon5:c.C244T:p.R82C		PS3	PM1	PM2		PP1	PP3	PP5								PS3,PM1,PM2,PP1,PP3,PP5	rs753986933	Pathogenic III(b)	**PMID:27016801 PS3: Rab27a R82C bound melanophilin, although to a lesser extent than wild-type Rab27a (Fig 2, A). In contrast, no Munc13-4 was detectable in the Rab27a R82C precipitate; PP1: Both homozygous patients (II.4 and II.5) have normal NK cell numbers but reduced CD107a mobilization, which could explain the severely decreased cytotoxic NK cell function. The homozygous siblings (II.3 and II.6) are less affected. The different cytotoxic responses observed for II.3 and II.5 could be caused by different percentages of NK cells detected for these patient. PMID:29357941 in chinese patient**
15	77324670	77324670	G	C	exonic	PSTPIP1	.		Benign/Likely_benign	not_specified	Pyogenic_arthritis,_pyoderma_gangrenosum_and_acne	0.011028	0.0078	0.0147764	0.0081	0.05114	T	P	3.648	SNV	nonsynonymous	PSTPIP1:NM_001321135:exon11:c.G773C:p.G258A,PSTPIP1:NM_003978:exon11:c.G773C:p.G258A,PSTPIP1:NM_001321136:exon12:c.G746C:p.G249A,PSTPIP1:NM_001321137:exon12:c.G986C:p.G323A									BS1	BS2			BP4	BP6	BS1,BS2,BP4,BP6	rs34240327	Benign (III)	
16	50733743	50733743	G	A	exonic	NOD2	.		Benign	.	0.007156	0.002	0.0698882	0.0017	0.005682	T	B	14.02	SNV	nonsynonymous	NOD2:NM_001293557:exon1:c.G337A:p.A113T,NOD2:NM_022162:exon2:c.G418A:p.A140T						PP2								BP4	BP6	PP2,BP4,BP6	rs34684955	Likely Benign (II)	
16	50744688	50744688	A	G	exonic	NOD2	.		Benign/Likely_benign	Crohn_disease	0.00554	0.0043	0.0339361	0.0044	0.001172	T	B	0.026	SNV	nonsynonymous	NOD2:NM_001293557:exon2:c.A785G:p.N262S,NOD2:NM_022162:exon4:c.A866G:p.N289S						PP2								BP4	BP6	PP2,BP4,BP6	rs5743271	Likely Benign (II)	
16	50744877	50744877	A	G	exonic	NOD2	.		Benign	.	0.003386	0.0011	0.0027953	0.0009	0.002345	D	B	15.93	SNV	nonsynonymous	NOD2:NM_001293557:exon2:c.A974G:p.H325R,NOD2:NM_022162:exon4:c.A1055G:p.H352R			PM1			PP2	PP3								BP6	PM1,PP2,PP3,BP6	rs5743272	VUS	
16	50744939	50744939	C	T	exonic	NOD2	.		not_provided	Sarcoidosis,_early-onset	0.000154	0.0002	0	0.0002	0.001758	T	B	16.54	SNV	nonsynonymous	NOD2:NM_001293557:exon3:c.C1036T:p.R346C,NOD2:NM_022162:exon4:c.C1117T:p.R373C			PM1			PP2								BP4		PM1,PP2,BP4	rs145293873	VUS	
16	50745868	50745868	G	T	exonic	NOD2	.		Likely_benign	Crohn_disease	Blau_syndrome	0.000154	0.0005	0.000199681	0.0004	0.002822	D	D	24.4	SNV	nonsynonymous	NOD2:NM_001293557:exon3:c.G1965T:p.L655F,NOD2:NM_022162:exon4:c.G2046T:p.L682F						PP2	PP3						BP6	PP2,PP3,BP6	rs149002807	VUS	
16	50745872	50745872	C	T	exonic	NOD2	.		Conflicting_interpretations_of_pathogenicity	Crohn_disease|Blau_syndrome	0.000385	0.0004	0.000199681	0.0004	0.005682	D	B	23.2	SNV	nonsynonymous	NOD2:NM_001293557:exon3:c.C1969T:p.R657W,NOD2:NM_022162:exon4:c.C2050T:p.R684W						PP2	PP3									PP2,PP3	rs5743276	VUS	
16	50745873	50745873	G	A	exonic	NOD2	.		.	.	0.000924	0.0003	0.00259585	0.0003	0.003612	T	B	7.749	SNV	nonsynonymous	NOD2:NM_001293557:exon3:c.G1970A:p.R657Q,NOD2:NM_022162:exon4:c.G2051A:p.R684Q						PP2								BP4		PP2,BP4	rs114664276	VUS	
16	50745926	50745926	C	T	exonic	NOD2	.		Conflicting_interpretations_of_pathogenicity_risk_factor	INFLAMMATORY_BOWEL_DISEASE_1_(CROHN_DISEASE)_SUSCEPTIBILITY_TO|not_specified|Crohn_disease|Blau_syndrome|YAO_SYNDROME,_SUSCEPTIBILITY_TO	0.031558	0.0227	0.014377	0.0259	0.002934	D	P	24.1	SNV	nonsynonymous	NOD2:NM_001293557:exon3:c.C2023T:p.R675W,NOD2:NM_022162:exon4:c.C2104T:p.R702W						PP2	PP3		BS1						PP2,PP3,BS1	rs2066844	VUS	
16	50745996	50745996	C	G	exonic	NOD2	.		Benign	Crohn_disease	Blau_syndrome	0.012927	0.0041	0.0183706	0.0031	0.00763	T	B	3.629	SNV	nonsynonymous	NOD2:NM_001293557:exon3:c.C2093G:p.A698G,NOD2:NM_022162:exon4:c.C2174G:p.A725G						PP2			BS1			BP4	BP6	PP2,BS1,BP4,BP6	rs5743278	Likely Benign (I)	
16	50746194	50746194	G	A	exonic	NOD2	.		Benign/Likely_benign	Sarcoidosis,_early-onset	Crohn_disease	Blau_syndrome	0.00177	0.0016	0.000199681	0.0016	0.001758	T	B	0.074	SNV	nonsynonymous	NOD2:NM_001293557:exon3:c.G2291A:p.R764Q,NOD2:NM_022162:exon4:c.G2372A:p.R791Q						PP2						BP4	BP6	PP2,BP4,BP6	rs104895464	Likely Benign (II)	
16	50746199	50746199	G	A	exonic	NOD2	.		Likely_benign	Sarcoidosis,_early-onset	Crohn_disease	0.001231	0.0011	0.000199681	0.0011	0.000586	D	B	22	SNV	nonsynonymous	NOD2:NM_001293557:exon3:c.G2296A:p.V766M,NOD2:NM_022162:exon4:c.G2377A:p.V793M						PP2	PP3			BS3			BP6	PP2,PP3,BS3,BP6	rs104895444	Likely Benign (I)	PMCID: PMC3378381; PMID: 12626759:BS3 Sixteen variants were indistinguishable from WT: R235C, T264S, R311W, H352R, N414S, S431L, A452V, E441K, R684W, R702C, A725Q, V793M, R796Q, M836V, V955I, and V972I.
16	50750810	50750810	A	G	exonic	NOD2	.		Conflicting_interpretations_of_pathogenicity_risk_factor	Sarcoidosis,_early-onset|not_specified|Crohn_disease|Blau_syndrome	0.000769	0.0012	0.000399361	0.0012	0.001172	D	D	23.6	SNV	nonsynonymous	NOD2:NM_001293557:exon5:c.A2474G:p.N825S,NOD2:NM_022162:exon6:c.A2555G:p.N852S		PS3		PM3		PP1	PP2	PP3							PS3,PM3,PP1,PP2,PP3	rs104895467	Likely pathogenic (III)	PM3:Mutation spectrum of NOD2 reveals recessive inheritance as a main driver of 2 Early Onset Crohn's Disease. We identified two individuals who are compound heterozygous for the p. G908R risk 129 allele in trans with a less common NOD2 CD risk variant (p.N852S) in one case and a novel 130 truncating indel (p.S506Vfs*73) in the second case PMID: 21983784 :PS3: Western blot analysis showed that the point mutations did not affect expression compared with the wild-type protein (Fig. 4). As published earlier28,29, the fs1007insC mutant did not induce NF-κB activation after MDP stimulation. The MDP-induced NF-κB activation was also impaired in the presence of S431L and N852S (Fig. 4).
16	50756540	50756540	C	G	exonic	NOD2	.		Conflicting_interpretations_of_pathogenicity_risk_factor	INFLAMMATORY_BOWEL_DISEASE_1_(CROHN_DISEASE)_SUSCEPTIBILITY_TO|not_specified|Blau_syndrome|Crohn_disease|YAO_SYNDROME,_SUSCEPTIBILITY_TO	0.010157	0.0099	0.00459265	0.0113	0.04885	D	D	31	SNV	nonsynonymous	NOD2:NM_001293557:exon7:c.G2641C:p.G881R,NOD2:NM_022162:exon8:c.G2722C:p.G908R			PM1			PP2	PP3		BS1	BS2					PM1,PP2,PP3,BS1,BS2	rs2066845	Benign (II)	
16	50756571	50756571	C	A	exonic	NOD2	.		Likely_benign	Sarcoidosis,_early-onset	Crohn_disease	Blau_syndrome	0.000539	0.0004	0.000599042	0.0006	0.002732	D	D	33	SNV	nonsynonymous	NOD2:NM_001293557:exon7:c.C2674A:p.A891D,NOD2:NM_022162:exon8:c.C2753A:p.A918D			PM1			PP2	PP3						BP6	PM1,PP2,PP3,BP6	rs104895452	VUS	
16	50759450	50759450	G	A	exonic	NOD2	.		not_provided	Sarcoidosis,_early-onset	0	3.31E-05	0	4.47E-05	0.009033	T	D	22.6	SNV	nonsynonymous	NOD2:NM_001293557:exon9:c.G2852A:p.G951E,NOD2:NM_022162:exon10:c.G2933A:p.G978E				PM2		PP2	PP3		BS3						PM2,PP2,PP3,BS3	rs104895457	VUS	PMID: 15044951:BS3:In contrast, multiple LRR mutants including A755V, G761S, L762M, V793M, I805N, P812T, D824N, A860G, L879I, Q889P, L891M, A892V, L904M, D915V, A923T, A944V, L947M, L948M, M956T, Q968H, G978E, S984T, K986I, A1002S, T1012IS, G1032C and L1038F exhibited a wild - type phenotype. sinversi of the rare CARD15/NOD2 variants found in CD patients, including A14GT, R373C, V793M and G978E, exhibited wild - type function, suggesting that they likely represent neutral polymorphisms without clinical significance
17	73826491	73826491	G	A	exonic	UNC13D	.		Benign/Likely_benign	not_specified	Familial_hemophagocytic_lymphohistiocytosis	0.015866	0.0299	0.0103834	0.0192	0.02709	T	B	15.21	SNV	nonsynonymous	UNC13D:NM_199242:exon9:c.C2782T:p.R928C			PM1						BS1	BS2			BP4	BP6	PM1,BS1,BS2,BP4,BP6	rs35037984	Benign (II)	
17	73831953	73831953	G	A	exonic	UNC13D	.		Benign/Likely_benign	not_provided	not_specified	Familial_hemophagocytic_lymphohistiocytosis	0.017915	0.0052	0.1191693	0.0038	0.002022	D	P	24	SNV	nonsynonymous	UNC13D:NM_199242:exon18:c.C1575T:p.R537W							PP3		BS1				BP6	PP3,BS1,BP6	rs75368116	Likely Benign (I)	
17	73836317	73836317	T	C	exonic	UNC13D	.		Benign	not_specified	0.009073	0.0025	0.00938498	0.0019	0.000586	D	B	24.4	SNV	nonsynonymous	UNC13D:NM_199242:exon10:c.A847G:p.I283V							PP3							BP6	PP3,BP6	rs61754871	VUS	
17	73837042	73837042	T	C	exonic	UNC13D	.		.	.	0.001	0.0006	0.000399361	0.0007	0.001594	D	B	22.6	SNV	nonsynonymous	UNC13D:NM_199242:exon7:c.A610G:p.M204V			PM1				PP3									PM1,PP3	rs144722609	VUS	
17	73839326	73839326	C	T	exonic	UNC13D	.		Benign	not_specified	0.016146	0.0159	0.0155751	0.0158	0.1881	D	B	21.6	SNV	nonsynonymous	UNC13D:NM_199242:exon3:c.G175A:p.A59T							PP3		BS1	BS2	BS4			BP6	PP3,BS1,BS2,BS4,BP6	rs9904386	Benign (II)	BS4:https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2141.2009.07729.x: See pedigree
17	78155422	78155422	G	A	exonic	CARD14	.		Benign	not_provided	0.0044	0.0026	0.0053937	0.0013	0.005682	T	B	4.483	SNV	nonsynonymous	CARD14:NM_001257970:exon2:c.G185A:p.R62Q,CARD14:NM_024110:exon2:c.G185A:p.R62Q			PM1										BP4	BP6	PM1,BP4,BP6	rs115582620	Likely Benign (II)	

17	78157888	78157888	G	C	exonic	CARD14	.	Benign	.	0.000231	0.005	0.00459265	0.0029	0.001175	D	P	26.7	nonsynonymous SNV	CARD14:NM_001257970:exon4:c.G526C:p.D176H,CARD14:NM_024110:exon4:c.G526C:p.D176H			PS3				PP3						BP6		PS3,PP3,BP6	rs144475004	VUS	PMCID: PMC3376540; PS3: Several rare variants (p.Glu142Lys, p.Glu142Gly, and p.Asp176His [rs144475004 (CARD14)]) in the coiled-coiled domain increased NF-kB activation two to five times more than did wild-type CARD14ah. Two variants clustered together: c.526C>C (p.Asp176His) (rs144475004 (CARD14)) and c.536G>A (p.Arg179His). Both amino acid substitutions were predicted to be damaging by PolyPhen2,27 and both lead to upregulation of NF-kB activation (2.78- and 1.38-fold increases, respectively) Compared with wild-type CARD14ah, a third variant, p.Asp176His (rs144475004 (CARD14)), leads to enhanced NF-kB activation. However, its frequency was similar in cases and controls, and it didn't increase NF-kB activity in vitro as much as other variants did. Hence, it might lie below the NF-kB-activation threshold required for disease. 26203641 PS3 = blotting of whole-cell extracts showed compQIAARAble transfection efficiencies for the two constructs (Figure 2c), the analysis of soluble proteins demonstrated that the p.Asp176His change was associated with a significant decrease in the levels of free CARD14 (Figure 2d and e). This suggested that the mutant protein was forming insoluble oligomers. To validate this hypothesis, we used the anti-FLAG antibody to analyze the insoluble fraction of the cell extracts. As predicted, we found that CARD14 aggregates were significantly more abundant in the cells that had been transfected with the p.Asp176His cDNA (Figure 2f and g). Interestingly, a similar effect was noted for the constructs harboring the p.Leu156Pro and p.Glu158Ala disease alleles (Figure 2d, e, f, and g). Thus, our findings indicate that the pathogenic potential of the p.Asp176His change is comp(QIAARA)ble with that of previously validated mutations.
17	78157951	78157951	G	A	exonic	CARD14	.	Uncertain_significance	not_specified	0.000309	0.0008	0.000559042	0.0005	0.000591	D	B	27.3	nonsynonymous SNV	CARD14:NM_001257970:exon4:c.G589A:p.E197K,CARD14:NM_024110:exon4:c.G589A:p.E197K			PS3				PP3								PS3,PP3	rs200790561	VUS	PMID: 26358359;PS3:These variants were c.349G>A (p.Gly117Ser), c.205C>T (p.Arg69Trp) and c.589G>A (p.Glu197Lys). c.589G>A (p.Glu197Lys) led to upregulation of NF-κB activity in a similar manner to that of previously descriQ(BED) psoriasis-associated mutations.
17	78178911	78178911	C	T	exonic	CARD14	.		.	0	0.0002	0	0.0003	0.003739	D	B	15.25	nonsynonymous SNV	CARD14:NM_024110:exon18:c.C2476T:p.R826W							PP3								PP3	rs139467141	VUS	
17	78179408	78179408	G	A	exonic	CARD14	.	Benign		0.001081	0.0122	0.2209665	0.0072	0.001832	T	B	9.374	nonsynonymous SNV	CARD14:NM_024110:exon19:c.G2648A:p.R883H				PM1					BS1				BP4	BP6	PM1,BS1,BP4,BP6	rs2289541	Likely Benign (I)	
18	2925284	2925284	G	A	exonic	LPIN2	.	Conflicting_interpretations_of_pathogenicity	not_specified	0.001615	0.003	0.00259585	0.0027	0.002181	T	B	0.4	nonsynonymous SNV	LPIN2:NM_014646:exon14:c.C1876T:p.P626S													BP4		BP4	rs150806357	VUS	
18	2925359	2925359	C	T	exonic	LPIN2	.	Benign/Likely_benign	not_specified	0.008919	0.0079	0.00519169	0.0089	0.04826	T	B	22	nonsynonymous SNV	LPIN2:NM_014646:exon14:c.G1801A:p.E601K										BS2			BP4	BP6	BS2,BP4,BP6	rs61735393	Likely Benign (I)	
18	2929103	2929103	G	A	exonic	LPIN2	.	Conflicting_interpretations_of_pathogenicity	Majeed_syndrome	not_specified	0.003385	0.0026	0.00199681	0.0026	0.002183	D	P	28.4	nonsynonymous SNV	LPIN2:NM_014646:exon10:c.C1510T:p.L504F				PM1			PP3			BS3						PM1,PP3,BS3	rs104895500	VUS	Molecular ChQ/ARA/cterization, Activity Assay Of Lipin2 Protein And Its Role In Psoriasis NCBI: BS3 :DNA analysis, SDS-PAGE and Western Blot analyses indicate that the Wild type and the six mutants are successfully sub-cloned and expressed in the expression hosts. Large scale expressions for all clones are carried out. The pure proteins were studied for their protein stability by CD spectroscopy and showed that there are no significant differences in stability. Read More: hIGME(TP)://www.cpcience.com/doi/abs/10.5339/qfarf.2013.BIOP-0142 he DNA analysis indicates that each fragment has been correctly cloned into the pYES2 vector. ChQ/ARA/cterization of the LPIN2 Gene and its Protein and Examination of its Role in Psoriasis BS3 The DNA analysis indicates that each fragment has been correctly cloned into the pYES2 vector.The analyses using SDS Gel Electrophoresis and Western Blot indicate that the Wild type and p.K387E are successfully expressed in S. cerevisiae strain p.S734L is expressed in S. cerevisiae but at a lower level. Expression experiments are being done on the 4 remaining mutant proteins.Read More: hIGME(TP)://www.cpcience.com/doi/abs/10.5339/qfarf.2011.bmp63
18	2937699	2937699	T	C	exonic	LPIN2	.	Benign/Likely_benign	Majeed_syndrome	not_specified	0.000615	0.0043	0.00678914	0.0039	0.007439	T	B	22.8	nonsynonymous SNV	LPIN2:NM_014646:exon7:c.A1159G:p.K387E				PM1						BS3			BP4	BP6	BS3,BP4,BP6	rs104895501	Likely Benign (I)	Molecular ChQ/ARA/cterization, Activity Assay Of Lipin2 Protein And Its Role In Psoriasis NCBI: BS3 :DNA analysis, SDS-PAGE and Western Blot analyses indicate that the Wild type and the six mutants are successfully sub-cloned and expressed in the expression hosts. Large scale expressions for all clones are carried out. The pure proteins were studied for their protein stability by CD spectroscopy and showed that there are no significant differences in stability. Read More: hIGME(TP)://www.cpcience.com/doi/abs/10.5339/qfarf.2013.BIOP-0142 he DNA analysis indicates that each fragment has been correctly cloned into the pYES2 vector. ChQ/ARA/cterization of the LPIN2 Gene and its Protein and Examination of its Role in Psoriasis BS3 The DNA analysis indicates that each fragment has been correctly cloned into the pYES2 vector.The analyses using SDS Gel Electrophoresis and Western Blot indicate that the Wild type and p.K387E are successfully expressed in S. cerevisiae strain p.S734L is expressed in S. cerevisiae but at a lower level. Expression experiments are being done on the 4 remaining mutant proteins.Read More: hIGME(TP)://www.cpcience.com/doi/abs/10.5339/qfarf.2011.bmp63
18	2937815	2937815	G	A	exonic	LPIN2	.	Benign/Likely_benign	Majeed_syndrome	not_specified	0.000461	0.0015	0.00119808	0.0013	0.002726	D	B	10.02	nonsynonymous SNV	LPIN2:NM_014646:exon7:c.C1043T:p.P348L			PS3										BP4	BP6	PS3,BP4,BP6	rs34676691	Likely Benign (II)	Molecular ChQ/ARA/cterization, Activity Assay Of Lipin2 Protein And Its Role In Psoriasis:PS3:The activity assay showed that one of the mutants (p.P348L) has higher phosphatase activity which a proximately two times more than the wild type. Read More: hIGME(TP)://www.cpcience.com/doi/abs/10.5339/qfarf.2013.BIOP-0142
18	2940693	2940693	G	A	exonic	LPIN2	.	Likely_benign	not_specified	Majeed_syndrome	0.000077	0.0043	0.00838658	0.0038	0.001172	T	B	22.3	nonsynonymous SNV	LPIN2:NM_014646:exon5:c.C608T:p.S203F													BP4	BP6	BP4,BP6	rs144555528	Likely Benign (II)	
19	7708058	7708058	C	T	exonic	STXBP2	.	Benign/Likely_benign	not_specified	0.011841	0.0109	0.00459265	0.0109	0.03831	D	D	26.3	nonsynonymous SNV	STXBP2:NM_001127396:exon13:c.C1025T:p.T342M,STXBP2:NM_001272034:exon13:c.C1067T:p.T356M,STXBP2:NM_006949:exon13:c.C1034T:p.T345M				PM1			PP3		BS1	BS2				BP6	PM1,PP3,BS1,BS2,BP6	rs117761837	Benign (III)	
19	7710134	7710134	C	T	exonic	STXBP2	.	Benign/Likely_benign	not_specified	0.008484	0.0158	0.0579073	0.0083	0.02898	T	B	15.23	nonsynonymous SNV	STXBP2:NM_001127396:exon15:c.C1289T:p.A430V,STXBP2:NM_001272034:exon15:c.C1331T:p.A444V,STXBP2:NM_006949:exon15:c.C1298T:p.A433V				PM1					BS1	BS2			BP4	BP6	PM1,BS1,BS2,BP4,BP6	rs141309384	Benign (III)	
19	7712364	7712364	A	G	exonic	STXBP2	.	Benign	not_specified	0.008931	0.0043	0.0121805	0.0028	0.005889	D	B	15.96	nonsynonymous SNV	STXBP2:NM_001127396:exon18:c.A1654G:p.R552G,STXBP2:NM_001272034:exon18:c.A1696G:p.R566G,STXBP2:NM_006949:exon18:c.A1663G:p.R555G				PM1			PP3		BS1					BP6	PM1,PP3,BS1,BP6	rs61735686	Likely Benign (I)	
19	54299165	54299165	G	A	exonic	NLRP12	.	Likely_benign	Familial_cold_autoinflammatory_syndrome	0.006074	0.0017	0.00419329	0.0012	0.00199	.	.	36	stopgain	NLRP12:NM_001277129:exon8:c.C2875T:p.R959X,NLRP12:NM_001277126:exon9:c.C3049T:p.R1017X,NLRP12:NM_144687:exon9:c.C3049T:p.R1016X				PM1										BP6	PM1,BP6	rs35064500	VUS	cannot mark PVS1 as NLRP12 has 9 exons and it falls in 9 exons
19	54313859	54313859	G	A	exonic	NLRP12	.	Pathogenic	.	0.000077	0.0004	0	0.0004	0.001172	D	P	24.1	nonsynonymous SNV	NLRP12:NM_001277136:exon3:c.C1054T:p.R352C,NLRP12:NM_001277129:exon3:c.C1054T:p.R352C,NLRP12:NM_144687:exon3:c.C1054T:p.R352C			PS3	PM1			PP3	PP5							PS3,PM1,PP3,PP5	rs199881207	Likely pathogenic (III)	PMID: 21538323:PS3:A heterozygous NLRP12 missense mutation involving a CpG site (c.1054C>T; p.Arg352Cys) was identified in exon 3, which encodes the nucleotide-binding site (NBS) of the protein, in 2 patients from different countries and carrying different NLRP12 hGME(AP)lotypes. The mutation, which does not alter the inhibitory effect of NLRP12 on NF-κB activation, increases speck formation and activates caspase 1 signaling. To define this new clase of PFS, we propose the term NLRP12-associated disorders (NLRP12AD).CONCLUSION:Given the rarity of known NLRP12-associated disorders, the identification of this NLRP12 molecular defect contributes to the deGIME/NEA)tion of the clinical spectrum associated with mutations in this gene and highlights the importance of screening NLRP12 in patients presenting with unexplained PFS. This study also demonstrates, by means of functional assays, the deleterious effect of this recurrent missense mutation; the gain of function for speck formation and caspase 1 signaling associated with this NBS mutation is consistent with the inflammatory phenotype of PFS.
19	54314003	54314003	G	A	exonic	NLRP12	.	Conflicting_interpretations_of_pathogenicity	not_specified	Familial_cold_autoinflammatory_syndrome	0.002691	0.0042	0.00219649	0.0044	0.007812	D	D	24	nonsynonymous SNV	NLRP12:NM_001277136:exon3:c.C910T:p.H304Y,NLRP12:NM_001277129:exon3:c.C910T:p.H304Y,NLRP12:NM_144687:exon3:c.C910T:p.H304Y				PM1			PP3								PM1,PP3	rs141245482	VUS	
19	54314063	54314063	G	A	exonic	NLRP12	.	Pathogenic	Familial_cold_autoinflammatory_syndrome_2	not_provided	0.000769	0.0002	0.00239617	0.0002	0.005682	.	.	33	stopgain	NLRP12:NM_001277136:exon3:c.C850T:p.R284X,NLRP12:NM_001277129:exon3:c.C850T:p.R284X,NLRP12:NM_144687:exon3:c.C850T:p.R284X	PVS1			PM1				PP5								PVS1,PM1,PP5	rs104895564	Pathogenic 1(c)	PVS1: NLRP12 has 9 exons and it falls in 3 exons https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0156981
19	55445884	55445884	C	T	exonic	NLRP7	.		.	0.002307	0.0007	0.00239617	0.0005	0.002657	T	B	0.157	nonsynonymous SNV	NLRP7:NM_001127255:exon7:c.G2444A:p.R815H,NLRP7:NM_139176:exon7:c.G2360A:p.R787H,NLRP7:NM_206828:exon7:c.G2444A:p.R815H													BP4		BP4	rs150034626	VUS	
19	55447773	55447773	G	A	exonic	NLRP7	.	not_provided	Hydatidiform_mole	0.000846	0.0012	0.000199681	0.0011	0.03731	D	B	15.89	nonsynonymous SNV	NLRP7:NM_001127255:exon6:c.C2156T:p.A719V,NLRP7:NM_139176:exon6:c.C2072T:p.A691V,NLRP7:NM_206828:exon6:c.C2156T:p.A719V							PP3			BS2						PP3,BS2	rs104895526	VUS	
19	55450655	55450655	T	C	exonic	NLRP7	.	Benign	not_specified	0.033831	0.0141	0.0247604	0.0131	0.02338	T	B	0.001	nonsynonymous SNV	NLRP7:NM_001127255:exon4:c.A1532G:p.K511R,NLRP7:NM_139176:exon4:c.A1532G:p.K511R,NLRP7:NM_206828:exon4:c.A1532G:p.K511R										BS1	BS2	BS4		BP4	BP6	BS1,BS2,BS4,BP4,BP6	rs61743949	Benign (III)	PMID:25082979:BS4: In contrast to the yeast system, the molecule to molecule interaction in HEK293T cells was clearly visible for the full-length wild-type NLRP7; the mutation R693P and the NSV K511R, while very faint for the two severe mutations, L398R and R993W. The less severe missense mutation R693P and the NSV K511R showed the same strong interaction with self-protein as the wild-type protein.
19	55450707	55450707	C	T	exonic	NLRP7	.		.	0.000384	0.0002	0	4.88E-05	0.01328	T	B	0.033	nonsynonymous SNV	NLRP7:NM_001127255:exon4:c.G1480A:p.A494T,NLRP7:NM_139176:exon4:c.G1480A:p.A494T,NLRP7:NM_206828:exon4:c.G1480A:p.A494T										BS2			BP4		BS2,BP4	rs61747407	Likely Benign (I)	
19	55450950	55450950	G	A	exonic	NLRP7	.		.	0.0016	0.0006	0.00179712	0.0004	0.001319	D	D	15.29	nonsynonymous SNV	NLRP7:NM_001127255:exon4:c.C1237T:p.R413W,NLRP7:NM_139176:exon4:c.C1237T:p.R413W,NLRP7:NM_206828:exon4:c.C1237T:p.R413W							PP3									PP3	rs148427076	VUS	
19	55450991	55450991	C	T	exonic	NLRP7	.	not_provided	Hydatidiform_mole	0	0.0005	0	0.0005	0.003063	D	D	22.3	nonsynonymous SNV	NLRP7:NM_001127255:exon4:c.G1196A:p.C399Y,NLRP7:NM_139176:exon4:c.G1196A:p.C399Y,NLRP7:NM_206828:exon4:c.G1196A:p.C399Y							PP3									PP3	rs104895510	VUS	
19	55451018	55451018	C	T	exonic	NLRP7	.		.	0.001697	0.0005	0.00279553	0.0005	0.001447	T	B	6.418	nonsynonymous SNV	NLRP7:NM_001127255:exon4:c.G1169A:p.R390H,NLRP7:NM_139176:exon4:c.G1169A:p.R390H,NLRP7:NM_206828:exon4:c.G1169A:p.R390H														BP4		BP4	rs141694326	VUS	